阿普米司特单药治疗未使用过生物制剂的银屑病关节炎患者的早期与持续疗效:一项IIIB期随机对照试验(ACTIVE)
在219例未使用过生物制剂的银屑病关节炎患者中,阿普米司特30 mg每日两次组第16周ACR20应答率显著高于安慰剂组(38.2% vs 20.2%,P=0.004),第2周即观察到疗效,并持续至第52周,安全性特征与既往报告一致。
要点
- 阿普米司特单药治疗未使用过生物制剂的PsA患者,第16周ACR20应答率38.2% vs 安慰剂20.2%(P=0.004)。
- 第2周首次评估时ACR20应答率阿普米司特组16.4% vs 安慰剂组6.4%(P=0.025)。
- 疗效持续至第52周,安全性特征与既往银屑病和PsA的3期研究一致。
核心结论
- 在未使用过生物制剂的银屑病关节炎患者中,阿普米司特的疗效在第2周即出现,并持续至第52周,安全性特征与既往报告一致。
研究设计与样本
- IIIB期随机对照试验,患者按1:1随机分配至阿普米司特30 mg每日两次组(n=110)或安慰剂组(n=109)。
- 第16周时,肿胀和压痛关节计数未改善≥10%的患者可提前 Escape;第24周起所有患者接受阿普米司特治疗至第52周。
主要发现
- 第16周ACR20应答率阿普米司特组38.2%(42/110)vs 安慰剂组20.2%(22/109),P=0.004。
- 第2周首次评估ACR20应答率阿普米司特组16.4%(18/110)vs 安慰剂组6.4%(7/109),P=0.025。
- 第16周DAS-28(CRP)变化(P<0.0001)、HAQ-DI变化(P=0.023)和Gladman附着点炎指数变化(P=0.001)阿普米司特组较安慰剂组显著改善。
- 第0-24周方案定义腹泻发生率阿普米司特组11.0% vs 安慰剂组8.3%;严重不良事件发生率阿普米司特组2.8% vs 安慰剂组4.6%。
关键数值与推荐
- 主要结局为第16周ACR20应答率,阿普米司特组38.2%(42/110)vs 安慰剂组20.2%(22/109),P=0.004。
- 第16周DAS-28(CRP)变化组间比较P<0.0001,HAQ-DI变化P=0.023,Gladman附着点炎指数变化P=0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naïve patients with PsA. METHODS: Patients were randomised (1:1) to apremilast 30 mg twice daily or placebo. At week 16, patients whose swollen and tender joint counts had not improved by ≥10% were eligible for early escape. At week 24, all patients received apremilast through week 52. RESULTS: Among 219 randomised patients (apremilast: n=110; placebo: n=109), a significantly greater American College of Rheumatology 20 response at week 16 (primary outcome) was observed with apremilast versus placebo (38.2% (42/110) vs 20.2% (22/109); P=0.004); response rates at week 2 (first assessment) were 16.4% (18/110) versus 6.4% (7/109) (P=0.025). Improvements in other efficacy outcomes, including 28-joint count Disease Activity Score (DAS-28) using C reactive protein (CRP), swollen joint count, Health Assessment Questionnaire-Disability Index (HAQ-DI), enthesitis and morning stiffness severity, were observed with apremilast at week 2. At week 16, apremilast significantly reduced PsA disease activity versus placebo, with changes in DAS-28 (CRP) (P<0.0001), HAQ-DI (P=0.023) and Gladman Enthesitis Index (P=0.001). Improvements were maintained with continued treatment through week 52. Over 52 weeks, apremilast's safety profile was consistent with prior phase 3 studies in psoriasis and PsA. During weeks 0-24, the incidence of protocol-defined diarrhoea was 11.0% (apremilast) and 8.3% (placebo); serious adverse event rates were 2.8% (apremilast) and 4.6% (placebo). CONCLUSIONS: In biological-naïve patients with PsA, onset of effect with apremilast was observed at week 2 and continued through week 52. The safety profile was consistent with previous reports. TRIAL REGISTRATION NUMBER: NCT01925768; Results.
引用
- Nash P, Ohson K, Walsh J, et al. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018. PMID: 29343507. doi:10.1136/annrheumdis-2017-211568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。